收稿日期: 2023-11-17
网络出版日期: 2024-07-09
基金资助
国家自然科学基金资助项目(82060489)
Expression of RSK4 gene in a variety of tumors and an analysis on the bioinformatics of this gene
Received date: 2023-11-17
Online published: 2024-07-09
目的 探讨在不同肿瘤细胞中核糖体S6蛋白激酶4（ribosomal protein S6 kinase 4， RSK4）的表达谱是否存在差异，以及预测可能存在的蛋白亚型及其生物学特性。 方法 提取神经胶质瘤细胞GL261、卵巢癌细胞ID8、乳腺癌细胞4T1和168FARN、结肠癌细胞mc38和CT26、胃癌细胞MFC和肺癌细胞LLC1的RNA，采用RT?PCR技术检测RSK4的表达及其剪接异构体，生物信息学分析RSK4的生物学特征及其功能。 结果 RT?PCR结果显示在GL261、4T1、mc38、CT26、MFC和LLC1中均表达RSK4，且不同的肿瘤细胞中表达了多个剪接异构体，开放阅读框分析RSK4可能至少编码11个蛋白亚型；二级结构分析显示，这些剪接异构体编码的蛋白亚型均由α?螺旋、延伸链、β?转角和无规则卷曲组成，且保守结构域均相同；蛋白互作网络富集分析显示，RSK4主要通过mTOR信号通路和突触持续增强等信号通路在核质和胞浆中发挥激酶的活性。 结论 RSK4在不同的肿瘤细胞中存在不同的表达谱，可能产生多种氮端不同的蛋白异构体，能够通过多种信号通路参与不同的生物学途径。
关键词： 核糖体S6蛋白激酶4; 转录本; 可变剪接; 生物信息学; 基因表达谱
杨江林 , 许远红 , 廖德仲 . 核糖体S6蛋白激酶4基因在多种肿瘤中的表达及其生物信息学分析[J]. 实用医学杂志, 2024 , 40(13) : 1778 -1784 . DOI: 10.3969/j.issn.1006-5725.2024.13.003
Objective The aim of this study was to investigate whether there are differences in the expression spectrums of RSK4 in different tumor cells and to predict the possible protein subtypes and their biological characteristics. Methods RNA was extracted from glioma cells GL261， ovarian cancer cells ID8， breast cancer cells 4T1 and 168FARN， colon cancer cells mc38 and CT26， gastric cancer cells MFC and lung cancer cells LLC1. The expressions and splicing isomers of RSK4 were detected by RT?PCR. The biological characteristics and functions of RSK4 were analyzed by bioinformatics. Results RT?PCR results showed that RSK4 was expressed in GL261， 4T1， mc38， CT26， MFC and LLC1； and multiple splicing isomers were expressed in different tumor cells. Open reading frame analysis revealed RSK4 may encode at least 11 protein subtypes. Secondary structure analysis showed that these protein subtypes encoded by the splicing isomers were composed of α?helix， extended strand， β?turn and random coil， and had the same conserved domain. The results of protein interaction network enrichment analysis showed that RSK4 exerted kinase activity in the nucleus and cytoplasm mainly through the mTOR signaling pathway and long?term potentiation. Conclusions RSK4 has different expression spectrums in different tumor cells， and may produces a variety of protein isoforms with different nitrogen terminals， which can be involved in different biological processes through multiple signaling pathways.
| 1 | YNTEMA H G， VAN DEN HELM B， KISSING J， et al. A novel ribosomal S6?kinase （RSK4； RPS6KA6） is commonly deleted in patients with complex X-linked mental retardation［J］. Genomics， 1999， 62（3）：332?343. doi:10.1006/geno.1999.6004 |
| 2 | XU J， JIA Q， ZHANG Y， et al. Prominent roles of ribosomal S6 kinase 4 （RSK4） in cancer［J］. Pathol Res Pract， 2021， 219： 153374. doi:10.1016/j.prp.2021.153374 |
| 3 | THAKUR A， XU H， WANG Y， et al. The role of X?linked genes in breast cancer［J］. Breast Cancer Res Treat， 2005， 93（2）： 135? 143. doi:10.1007/s10549-005-4516-0 |
| 4 | THAKUR A， RAHMAN K W， WU J， et al. Aberrant expression of X?linked genes RbAp46， Rsk4， and Cldn2 in breast cancer［J］. Mol Cancer Res， 2007， 5（2）： 171?181. doi:10.1158/1541-7786.mcr-06-0071 |
| 5 | THAKUR A， BOLLIG A， WU J， et al. Gene expression profiles in primary pancreatic tumors and metastatic lesions of Ela?c?myc transgenic mice［J］. Mol Cancer， 2008， 7：11. doi:10.1186/1476-4598-7-11 |
| 6 | THAKUR A， SUN Y， BOLLIG A， et al. Anti?invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells［J］. Clin Cancer Res， 2008， 14（14）： 4427?4436. doi:10.1158/1078-0432.ccr-08-0458 |
| 7 | SUN Y， CAO S， YANG M， et al. Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase?4［J］. Oncogene， 2013， 32（14）： 1794?1810. doi:10.1038/onc.2012.200 |
| 8 | NAGUMO Y， VILLAREAL M O， ISODA H， et al. RSK4 confers paclitaxel resistance to ovarian cancer cells， which is resensitized by its inhibitor BI?D1870［J］. Biochem Biophys Res Commun， 2023， 679： 23?30. doi:10.1016/j.bbrc.2023.08.060 |
| 9 | PANG F， ZHANG L， LI M， et al. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma［J］. Cancer Gene Ther， 2023， 30（12）： 1636?1648. doi:10.1038/s41417-023-00666-3 |
| 10 | STEVENS M， OLTEAN S. Modulation of the Apoptosis Gene Bcl?x Function Through Alternative Splicing［J］. Front Genet， 2019， 10：804. doi:10.3389/fgene.2019.00804 |
| 11 | 强晓， 耿贝贝， 刘四喜， 等. 转录组学技术在急性白血病诊治中的应用研究进展［J］. 实用医学杂志， 2023， 39（22）： 3010?3014. doi:10.3969/j.issn.1006-5725.2023.22.027 |
| 12 | SUN Y， SRIRAMAJAYAM K， LUO D， et al. A quick， cost?free method of purification of DNA fragments from agarose gel［J］. J Cancer， 2012， 3： 93?95. doi:10.7150/jca.4163 |
| 13 | 孙国瑞， 许军鹏， 罗利琼， 等. 核糖体S6蛋白激酶4在恶性肿瘤中研究进展［J］. 临床军医杂志， 2021， 49（3）：356?357，359. |
| 14 | 伍越， 杨华伟. RSK4与恶性肿瘤［J］. 中国癌症防治杂志， 2017， 9（4）： 326?328. doi:10.3969/j.issn.1674-5671.2017.04.17 |
| 15 | CHRYSOSTOMOU S， ROY R， PRISCHI F， et al. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer［J］. Sci Transl Med， 2021， 13（602）： eaba4627. doi:10.1126/scitranslmed.aba4627 |
| 16 | ARECHAVALETA?VELASCO F， DOMINGUEZ?LOPEZ P， ACOSTA?JIMENEZ E， et al. Ribosomal S6 kinase 4 （RSK4） tumor suppressor gene promoter methylation status in ovarian cancer［J］. Mol Biol Rep， 2023， 50（8）： 6863?6870. doi:10.1007/s11033-023-08609-9 |
| 17 | CHEN S， SECKL M J， LORENTZEN M P G， et al. Differential Expression of RSK4 Transcript Isoforms in Cancer and Its Clinical Relevance［J］. Int J Mol Sci， 2022， 23（23）： 14569. doi:10.3390/ijms232314569 |
| 18 | KORNBLIHTT A R， SCHOR I E， ALLó M， et al. Alternative splicing： a pivotal step between eukaryotic transcription and translation［J］. Nat Rev Mol Cell Biol， 2013， 14（3）： 153?165. doi:10.1038/nrm3525 |
| 19 | KHAN M R， WELLINGER R J， LAURENT B. Exploring the Alternative Splicing of Long Noncoding RNAs［J］. Trends Genet， 2021， 37（8）： 695?698. doi:10.1016/j.tig.2021.03.010 |
| 20 | RODRIGUEZ J M， POZO F， DOMENICO T D I， et al. An analysis of tissue?specific alternative splicing at the protein level［J］. PLoS Comput Biol， 2020， 16（10）： e1008287. doi:10.1371/journal.pcbi.1008287 |
| 21 | XIONG W， GAO D， LI Y， et al. Genome?wide profiling of chemoradiation?induced changes in alternative splicing in colon cancer cells［J］. Oncol Rep， 2016， 36（4）： 2142?2150. doi:10.3892/or.2016.5022 |
| 22 | YANG C， WU Q， HUANG K， et al. Genome?Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma［J］. Front Oncol， 2019， 9：511. doi:10.3389/fonc.2019.00511 |
| 23 | DANAN?GOTTHOLD M， GOLAN?GERSTL R， EISENBERG E， et al. Identification of recurrent regulated alternative splicing events across human solid tumors［J］. Nucleic Acids Res， 2015， 43（10）： 5130?5144. doi:10.1093/nar/gkv210 |
| 24 | ZHANG D， HU Q， LIU X， et al. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer［J］. Nat Commun， 2020， 11（1）： 2089. doi:10.1038/s41467-020-15815-7 |
| 25 | KELEMEN O， CONVERTINI P， ZHANG Z， et al. Function of alternative splicing［J］. Gene， 2013， 514（1）： 1?30. doi:10.1016/j.gene.2012.07.083 |
| 26 | SINGH A， RAJEEVAN A， GOPALAN V， et al. Broad misappropriation of developmental splicing profile by cancer in multiple organs［J］. Nat Commun， 2022， 13（1）： 7664. doi:10.1038/s41467-022-35322-1 |
/
| 〈 |
|
〉 |